Abiopharma

🔍 Munch Mark (Executive)

Company: BRUKER CORP (BRKR)

Report Date: 2026-01-05

Detailed Transactions and Holdings:

• Acquired 4,506 shares of Common Stock at $22.19 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 132,949.00 | transaction_form_type: 4
• Acquired 14,000 shares of Common Stock at $22.19 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 146,949.00 | transaction_form_type: 4
• Acquired 15,337 shares of Common Stock at $22.19 per share (Direct)
  Date: 2026-01-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 162,286.00 | transaction_form_type: 4
• Sold 4,506 shares of Common Stock at $50.0 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 157,780.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 14,000 shares of Common Stock at $50.0 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 143,780.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 15,337 shares of Common Stock at $49.25 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 128,443.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,506 shares of Stock Option (Right to Purchase) at $22.19 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2026-10-04 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Sold 14,000 shares of Stock Option (Right to Purchase) at $22.19 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2026-10-04 | equity_swap_involved: 0 | shares_owned_after: 40,337.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 15,337 shares of Stock Option (Right to Purchase) at $22.19 per share (Derivative)
  Date: 2026-01-05 | Code: M | Expires: 2026-10-04 | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.74 to $50.065, inclusive. The reporting person undertakes to provide to Bruker Corporation, any security holder of Bruker Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The stock option granted to the Reporting Person on October 4, 2016 (the "Original Grant Date") vests in full on the fourth anniversary of the Original Grant Date.
• F4: The stock option granted to the Reporting Person on October 4, 2016 (the "Original Grant Date") vests in equal installments on the first, second, third and fourth anniversaries of the Original Grant Date.